Abaxis (ABAX) beat estimates with reported Q3 Revenues of $35.3M/$0.17 up 17% over last year’s comparable quarter. Cash position is $100.6M up from $87.6M last year’s Q3. March ’11 Fiscal Year estimates are $143M and $0.72/sh. Shares are up 0.97% today to $24 level up from low of $22.40 on Wednesday.
GenProbe (GPRO) reported Q3 Revenues/EPS of $133m/$0.57 vs consensus of $135M/$0.50 a slight miss on the top line. Blood screening sales are stable and new products HPV and Panther schedules remain on track. Guidance has been lowered to $541-546M/$2.12-$2.25 reflecting lower healthcare utilization trends.Market Cap $2.4B with $8.70 cash per share. No major impact on stock down 0.7% to $48.72.
The Rayno LifeScience Model Portfolio is up 21.5% including 2010 rebalancing.